Migalastat Sales Forecast, and Market Size Analysis - 2034
상품코드:1938033
리서치사:DelveInsight
발행일:On Demand Report
페이지 정보:영문 30 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
미갈라스타트의 성장을 견인하는 주요 요인
1. 시장 점유율 확대 및 신규 환자 수 증가
미갈라스타트는 패브리병 시장에서 특히 치료 적응이 되는 GLA 돌연변이를 가진 환자층을 중심으로 점유율을 계속 확대하고 있습니다. 이것은 정밀의료에 대한 인식이 높아지고 있다는 것이 배경에 있습니다.
유전자 스크리닝률의 상승과 조기 진단에 의해 치료 대상이 되는 환자층이 확대되어, 세계적으로 신규 치료 개시가 촉진되고 있습니다.
Amicus Therapeutics의 환자 지원 프로그램, 진단 파트너십 및 의사 교육 이니셔티브는 기존의 효소 보충 요법(ERT)과 비교하여 미갈라스타트의 채택을 강화하고 있습니다.
2. 주요 적응증에서의 확대
패브리병(치료가능한 돌연변이) : 미갈라스타트는 치료가능한 GLA 돌연변이를 가진 패브리병의 성인 및 청소년(12세 이상, 체중 45kg 이상)에 대해 승인을 받았으며 근본적인 단백질 오폴딩 이상을 대처합니다.
심장 패브리병 아형 : 패브리병 관련 심근병증 환자에서의 사용이 증가하고 있으며, 좌심실 질량 지수(LVMI)의 안정화 또는 개선을 나타내는 데이터가 별도로 뒷받침되고 있습니다.
신장 병변 : 조기부터 중등도의 신장 기능 장애를 가진 환자에 대한 채용이 확대되고 있습니다. 연구는 지속적인 신장 기능 안정화가 입증되었기 때문입니다.
파이프라인 바이오마커 확대 : 돌연변이 재분류 및 바이오마커 기반 환자 식별에 대한 연구가 진행 중이며 적격 치료 대상 환자의 확대가 기대됩니다.
3. 지리적 확대
미갈라스타트는 미국, EU, 영국, 일본, 아시아태평양 및 라틴아메리카의 여러 국가에서 판매됩니다.
유럽과 일본은 계속 견조한 시장이지만, 아시아태평양의 신흥 시장에서는 유전자 검사 및 희귀질환 치료에 대한 액세스 개선으로 보다 빠른 성장을 볼 수 있습니다.
Amicus는 지역별 유통 네트워크, 진단 협력 체제 및 상환 경로를 강화함으로써 보급 촉진을 위해 노력하고 있습니다.
4. 신규 적응증 승인
규제 당국은 미갈라스타트의 적응증을 치료 가능한 패브리병 변이를 가진 청소년기 환자로 확대하고 치료 대상 환자층을 확대했습니다.
현재 진행 중인 실제 임상에서 돌연변이의 재분류 노력은 치료가능한 것으로 간주되는 변이체의 수를 증가시키고, 간접적으로 미갈라스타트의 임상 사용 범위를 확대하고 있습니다.
보건 당국은 자격을 갖춘 환자에서 효소 보충 요법(ERT)의 첫 번째 선택 대체 요법으로 경구 샤페론 요법을 반영하기 위해 Fabry 질병 치료 지침을 계속 업데이트하고 있습니다.
5. 패브리병에서의 강한 치료 규모의 성장 모멘텀
패브리병은 여전히 성장의 핵심이며, 환자가 격주 점적 요법에서 경구 요법으로 전환함에 따라 처방량이 꾸준히 증가하고 있습니다.
장기 추적 데이터는 신장, 심장 및 생화학적 효과의 지속성을 나타내며 의사의 지속적인 신뢰를 지원합니다.
리얼 월드 에비던스에서는 높은 치료 계속률과 생활의 질의 향상이 확인되어 미갈라스타트가 만성 경구 치료로서의 역할을 강화하고 있습니다.
6. 경쟁상의 차별화 및 시장 동향
경구 저분자 샤페론 요법은 정맥내 효소 보충 요법에 비해 편리성에 큰 우위를 가지며, 복약 준수율 및 환자 만족도의 향상에 기여하고 있습니다.
미갈라스타트의 정밀의료 접근(돌연변이 특이 적 치료)은 유전자 표적 치료의 광범위한 동향을 따릅니다.
양호한 장기 안전성 및 내약성 데이터는 젊은층과 상태가 안정된 환자에게 사용을 지지합니다.
실제 세계 증거와 레지스트리 데이터에 대한 의존도가 높아짐에 따라 지불 기관과 임상의의 미갈라스타트에 대한 신뢰성이 향상되었습니다.
이 보고서는 패브리병과 같은 승인 적응증에 대해 주요 7개국(미국, EU4(독일, 프랑스, 이탈리아, 스페인), 영국)에서 미갈라스타트의 종합적인 인사이트를 제공합니다. 2020-2034년 주요 7개국에서 미갈라스타트의 승인 적응증 및 잠재 적응증에서의 사용 상황, 진입 전망, 실적에 대한 상세한 전망을 제공함과 동시에, 승인 적응증 및 잠재 적응증에서의 미갈라스타트에 대한 상세한 설명을 제시합니다. 또한 이 약제의 매출 예측, 작용기전(MoA), 투여량 및 투여 방법, 규제상의 이정표를 포함한 연구개발 및 기타 활동에 관한 지견을 제공합니다. 또한 과거 및 현재 미갈라스타트의 실적, 미래 시장 평가, SWOT 분석, 분석가의 견해, 경쟁업체의 종합적 개요, 각 적응증에 대한 기타 신흥 치료법의 개요, 매출 예측 분석, 시장 견인 요인 등도 정리했습니다.
목차
제1장 보고서 개요
제2장 미갈라스타트의 개요 : 패브리병 등의 승인 적응증
제품 상세
임상 개발
임상 연구
임상시험 정보
안전성 및 유효성
기타 개발 활동
제품 프로파일
제3장 미갈라스타트 : 경쟁 구도(출시 끝난 치료제)
제4장 미갈라스타트 : 경쟁 구도(개발 후기 치료제)
제5장 미갈라스타트 : 시장 평가
승인된 적응증에 대한 시장 전망
주요 7개국 분석
승인된 적응증 시장 규모
국가별 시장 분석
미국
독일
영국
제6장 미갈라스타트 : SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 정보
제12장 보고서 구매 옵션
AJY
영문 목차
영문목차
Key Factors Driving Migalastat Growth
1. Market Share Gains and New Patient Starts
Migalastat continues to gain share in the Fabry disease market, particularly among patients with amenable GLA mutations, as awareness of precision therapy grows.
Rising genetic screening rates and earlier diagnosis are increasing the pool of eligible patients, driving new treatment starts globally.
Amicus Therapeutics' patient support programs, diagnostic partnerships, and physician education initiatives are strengthening Migalastat adoption versus traditional enzyme replacement therapies (ERTs).
2. Expansion Across Key Indications
Fabry Disease (Amenable Mutations): Migalastat is approved for adults and adolescents (>=12 years, >=45 kg) with Fabry disease who carry amenable GLA variants, addressing the underlying protein misfolding defect.
Cardiac Fabry Subtype: Increasing use in patients with Fabry-related cardiomyopathy, supported by data showing stabilization or improvement in left ventricular mass index (LVMI).
Renal Involvement: Growing adoption in patients with early to moderate renal impairment, as studies demonstrate durable renal function stabilization.
Pipeline Biomarker Expansion: Ongoing research into mutation reclassification and biomarker-driven patient identification is expected to expand the eligible treatment population.
3. Geographic Expansion
Migalastat is marketed across the US, EU, UK, Japan, and multiple Asia-Pacific and Latin American countries.
Europe and Japan remain strong markets, while emerging markets in Asia-Pacific are showing faster growth due to improved access to genetic testing and rare disease care.
Amicus is strengthening regional distribution networks, diagnostic collaborations, and reimbursement pathways to accelerate uptake.
4. New Indication Approvals
Regulatory agencies have expanded Migalastat's label to include adolescents with amenable Fabry mutations, increasing the treatable population.
Ongoing real-world mutation reclassification efforts are increasing the number of variants deemed amenable, indirectly broadening Migalastat's clinical use.
Health authorities continue to update Fabry treatment guidelines to reflect oral chaperone therapy as a first-line alternative to ERT in eligible patients.
5. Strong Volume Momentum in Fabry Disease
Fabry disease remains the core growth driver, with consistent prescription growth as patients switch from bi-weekly infusions to oral therapy.
Long-term follow-up data demonstrate durable renal, cardiac, and biochemical benefits, supporting continued physician confidence.
Real-world evidence shows high treatment persistence and improved quality of life, reinforcing Migalastat's role as a chronic oral therapy.
6. Competitive Differentiation and Market Trends
Oral small-molecule chaperone therapy offers major convenience advantages over intravenous enzyme replacement, improving adherence and patient satisfaction.
Favorable long-term safety and tolerability data support use in younger and stable patients.
Growing reliance on real-world evidence (RWE) and registry data is strengthening payer and clinician confidence in Migalastat.
Migalastat Recent Developments
Strong European and US performance, supported by higher genetic testing rates and new Fabry diagnoses.
Ongoing real-world registry and long-term extension studies confirming sustained renal and cardiac benefits.
Expansion of adolescent treatment populations in key markets.
"Migalastat Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Migalastat for approved indication like Fabry's disease in the 7MM. A detailed picture of Migalastat's existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Migalastat for approved indications. The Migalastat market report provides insights about Migalastat's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Migalastat performance, future market assessments inclusive of the Migalastat market forecast analysis for approved indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Migalastat sales forecasts, along with factors driving its market.
Migalastat Drug Summary
Migalastat (Galafold) is an oral pharmacological chaperone specifically indicated for the long-term treatment of Fabry disease in adults and adolescents aged 16 years and older with amenable mutations in the alpha-galactosidase A (a-Gal A) gene (GLA), affecting approximately 35-50% of Fabry patients. It reversibly binds to the active site of mutant a-Gal A enzyme, stabilizing its proper folding, facilitating trafficking from the endoplasmic reticulum to the lysosome, and enhancing residual enzyme activity to reduce globotriaosylceramide (GL-3) substrate accumulation in tissues such as kidney, heart, and plasma, thereby slowing disease progression including renal dysfunction and cardiac hypertrophy. Administered as 123 mg capsules every other day without food, migalastat offers a convenient alternative to enzyme replacement therapy for eligible patients, with amenability confirmed via in vitro assays. The report provides Migalastat's sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the Migalastat Market Report
The report provides insights into:
A comprehensive product overview including the Migalastat MoA, description, dosage and administration, research and development activities in approved indication like Fabry's disease.
Elaborated details on Migalastat regulatory milestones and other development activities have been provided in Migalastat market report.
The report also highlights Migalastat's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
The Migalastat market report also covers the patents information, generic entry and impact on cost cut.
The Migalastat market report contains current and forecasted Migalastat sales for approved indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The Migalastat market report also features the SWOT analysis with analyst views for Migalastat in approved indications.
Methodology:
The Migalastat market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Migalastat Analytical Perspective by DelveInsight
In-depth Migalastat Market Assessment
This Migalastat sales market forecast report provides a detailed market assessment of Migalastat for approved indication like Fabry's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Migalastat sales data uptil 2034.
Migalastat Clinical Assessment
The Migalastat market report provides the clinical trials information of Migalastat for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.
Migalastat Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
Migalastat Market Potential & Revenue Forecast
Projected market size for the Migalastat and its key indications
Commercial partnerships, licensing deals, and M&A activity
Migalastat Clinical Differentiation
Migalastat Efficacy & safety advantages over existing drugs
Migalastat Unique selling points
Migalastat Market Report Highlights
In the coming years, the Migalastat market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The Migalastat companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Migalastat's dominance.
Other emerging products for Fabry's disease are expected to give tough market competition to Migalastat and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Migalastat in approved indications.
Analyse Migalastat cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted Migalastat sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Migalastat in approved indications.
Key Questions:
What is the class of therapy, route of administration and mechanism of action of Migalastat? How strong is Migalastat's clinical and commercial performance?
What is Migalastat's clinical trial status in each individual indications such as Fabry's disease and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Migalastat Manufacturers?
What are the key designations that have been granted to Migalastat for approved indications? How are they going to impact Migalastat's penetration in various geographies?
What is the current and forecasted Migalastat market scenario for approved indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of Migalastat in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to Migalastat for approved indications?
Which are the late-stage emerging therapies under development for the treatment of approved indications?
How cost-effective is Migalastat? What is the duration of therapy and what are the geographical variations in cost per patient?
Table of Contents
1. Report Introduction
2. Migalastat Overview in approved indications like Fabry's disease
